Risk Exposure: Using Cases in Strategies Involving an Aging Medication

  • Martin CalkinsEmail author
Part of the Issues in Business Ethics book series (IBET, volume 42)


Explains the history of a controversial and aging breast cancer preventative drug called tamoxifen, the risk assessment processes used to determine whether or not to continue to aggressively market a medication that remains beneficial to some but not all, the risks associated with moral lacunae, and how virtue-imbued casuistry can fortify current risk analysis processes.


Breast Cancer Risk Exposure Androgenic Anabolic Steroid Aging Drug Tamoxifen Citrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Netherlands 2014

Authors and Affiliations

  1. 1.Department of Management and MarketingUniversity of Massachusetts, Boston College of ManagementBostonUSA

Personalised recommendations